Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Non-Small Cell Lung Cancer

Oncolytics Biotech Inc. (ONCY announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic non-small cell lung cancer.